Literature DB >> 28191619

Hypothyroidism reduces mammary tumor progression via Β-catenin-activated intrinsic apoptotic pathway in rats.

C M López Fontana1, L E Zyla2, F E Santiano2, C V Sasso2, F D Cuello-Carrión2, V Pistone Creydt2, M A Fanelli2, R W Carón2.   

Abstract

Experimental hypothyroidism retards mammary carcinogenesis promoting apoptosis of tumor cells. β-catenin plays a critical role in cell adhesion and intracellular signaling pathways conditioning the prognosis of breast cancer. However, the mechanistic connections associated with the expression of β-catenin in thyroid status and breast cancer are not known. Therefore, we studied the relationship between the expression and localization of β-catenin and apoptosis in mammary tumors induced by 7,12-dimethylbenz(a)anthracene (DMBA) in hypothyroid (Hypot) and euthyroid (EUT) rats. Female Sprague Dawley rats were treated with a dose of DMBA (15 mg/rat) at 55 days of age and were then divided into two groups: HypoT (0.01% 6-N-propyl-2-thiouracil in drinking water, n = 54) and EUT (untreated control, n = 43). Latency, incidence and progression of tumors were determined. At sacrifice, tumors were obtained for immunohistological studies and Western Blot. The latency was longer (p < 0.05), the incidence was lower (p < 0.0001) and tumor growth was slower (p < 0.01) in HypoT rats compared to EUT. The expression of Bax, cleaved caspase-9 and caspase-3 was significantly higher in tumors of HypoT than in EUT (p < 0.05) indicating the activation of the intrinsic pathway. In this group, β-catenin was expressed in the plasma membrane and with less intensity, while its expression was nuclear and with greater intensity in the EUT (p < 0.05). Moreover, the expression of survivin was reduced in tumors of HypoT rats (p < 0.05). In conclusion, decreased expression of β-catenin and its normal location in membrane of mammary tumors are associated with augmented apoptosis via activation of the intrinsic pathway in HypoT rats.

Entities:  

Keywords:  Bax; Caspase-3; Caspase-9; Dimethylbenz(a)anthracene; Survivin

Mesh:

Substances:

Year:  2017        PMID: 28191619     DOI: 10.1007/s00418-017-1544-x

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  66 in total

1.  Wnt/beta-catenin signaling suppresses apoptosis in low serum medium and induces morphologic change in rodent fibroblasts.

Authors:  Yoshihide Ueda; Makoto Hijikata; Shinji Takagi; Ritsuko Takada; Shinji Takada; Tsutomu Chiba; Kunitada Shimotohno
Journal:  Int J Cancer       Date:  2002-06-10       Impact factor: 7.396

Review 2.  Nod-like proteins in immunity, inflammation and disease.

Authors:  Jörg H Fritz; Richard L Ferrero; Dana J Philpott; Stephen E Girardin
Journal:  Nat Immunol       Date:  2006-12       Impact factor: 25.606

3.  The expression of β-catenin in different subtypes of breast cancer and its clinical significance.

Authors:  Shuguang Li; Shanshan Li; Ying Sun; Li Li
Journal:  Tumour Biol       Date:  2014-05-08

4.  Breast cancer in patients with Hashimoto's thyroiditis.

Authors:  K Ito; N Maruchi
Journal:  Lancet       Date:  1975-12-06       Impact factor: 79.321

Review 5.  Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective.

Authors:  Lars C Moeller; Dagmar Führer
Journal:  Endocr Relat Cancer       Date:  2013-03-22       Impact factor: 5.678

6.  Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis.

Authors:  Pengfei Li; Youming Guo; Grant Bledsoe; Zhirong Yang; Lee Chao; Julie Chao
Journal:  Exp Cell Res       Date:  2016-01-11       Impact factor: 3.905

Review 7.  The Modulation of Apoptotic Pathways by Gammaherpesviruses.

Authors:  Shuvomoy Banerjee; Timsy Uppal; Roxanne Strahan; Prerna Dabral; Subhash C Verma
Journal:  Front Microbiol       Date:  2016-04-27       Impact factor: 5.640

8.  Hypothyroidism enhances tumor invasiveness and metastasis development.

Authors:  Olaia Martínez-Iglesias; Susana García-Silva; Javier Regadera; Ana Aranda
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

9.  Bcl-XL inhibits membrane permeabilization by competing with Bax.

Authors:  Lieven P Billen; Candis L Kokoski; Jonathan F Lovell; Brian Leber; David W Andrews
Journal:  PLoS Biol       Date:  2008-06-10       Impact factor: 8.029

10.  Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K/Akt enhanced β-catenin/Tcf-Lef dependent transcription.

Authors:  Jaime G Fernández; Diego A Rodríguez; Manuel Valenzuela; Claudia Calderon; Ulises Urzúa; David Munroe; Carlos Rosas; David Lemus; Natalia Díaz; Mathew C Wright; Lisette Leyton; Julio C Tapia; Andrew Fg Quest
Journal:  Mol Cancer       Date:  2014-09-09       Impact factor: 27.401

View more
  5 in total

1.  In focus in HCB.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2017-04-29       Impact factor: 4.304

2.  Thyroid disease is associated with an increased risk of breast cancer: a systematic review and meta-analysis.

Authors:  Shi Chen; Fei Wu; Rui Hai; Qian You; Linjun Xie; Liang Shu; Xiangyu Zhou
Journal:  Gland Surg       Date:  2021-01

3.  Hypothyroidism and the risk of breast cancer recurrence and all-cause mortality - a Danish population-based study.

Authors:  Anne Mette Falstie-Jensen; Anders Kjærsgaard; Ebbe Laugaard Lorenzen; Jeanette Dupont Jensen; Kristin Valborg Reinertsen; Olaf M Dekkers; Marianne Ewertz; Deirdre P Cronin-Fenton
Journal:  Breast Cancer Res       Date:  2019-03-22       Impact factor: 6.466

4.  Cancer-specific mortality in breast cancer patients with hypothyroidism: a UK population-based study.

Authors:  Lauren McVicker; Christopher R Cardwell; Stuart A McIntosh; Úna C McMenamin
Journal:  Breast Cancer Res Treat       Date:  2022-07-31       Impact factor: 4.624

5.  Does hypothyroidism increase the risk of breast cancer: evidence from a meta-analysis.

Authors:  Bolin Wang; Zhong Lu; Yan Huang; Ruobao Li; Tao Lin
Journal:  BMC Cancer       Date:  2020-08-06       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.